Skip to main content
Erschienen in:

26.05.2020 | short review

Myeloid diseases—Chronic Myeloid Leukemia (CML)—report from ASH 2019 on new developments

verfasst von: Prim. Univ.-Prof. Dr. Andreas L. Petzer

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Summary

The recent American Society of Hematology (ASH) annual meeting, held in Orlando, Florida, in December 2019 was an exciting meeting for researchers and clinicians working in the field of chronic myeloid leukemia (CML), as well as for patients suffering from the disease. Interesting updates were presented on new kinase inhibitors (TKI) demonstrating great potential with low toxicities in heavily pretreated patients. Moreover, the 10-year follow-up data of the ENESTnd Study, comparing 2nd generation (2ndG) TKI nilotinib with imatinib showed a continuous benefit of the 2ndG TKI in achieving deeper molecular responses and less progressions to accelerated phase (AP) and blast crisis (BC), but no benefit in progression-free (PFS) or overall survival (OS). Encouraging data were also presented on the treatment of CML BC by combining conventional chemotherapy (FLAG-IDA) with TKI therapy (Ponatinib). Furthermore, great efforts have been undertaken to be able to predict the likelihood of successful TKI cessation in deep molecular remission for individual CML patients in first chronic phase (CP).
Literatur
1.
Zurück zum Zitat Ren X, Pan X, Zhang Z, et al. Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. J Med Chem. 2013;56(3):879–94. https://doi.org/10.1021/jm301581y.CrossRefPubMed Ren X, Pan X, Zhang Z, et al. Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. J Med Chem. 2013;56(3):879–94. https://​doi.​org/​10.​1021/​jm301581y.CrossRefPubMed
2.
Zurück zum Zitat Jiang Q, Huang X, Chen Z, et al. An updated safety and efficacy results of phase 1 study of HQP1351, a novel 3 rd generation of BRC-ABL Tyrosine Kinase Inhibitor (TKI), in patients with resistant chronic myeloid leukemia. Blood. 2019;134(Supplement_1):493. https://doi.org/10.1182/blood-2019-124295.CrossRef Jiang Q, Huang X, Chen Z, et al. An updated safety and efficacy results of phase 1 study of HQP1351, a novel 3 rd generation of BRC-ABL Tyrosine Kinase Inhibitor (TKI), in patients with resistant chronic myeloid leukemia. Blood. 2019;134(Supplement_1):493. https://​doi.​org/​10.​1182/​blood-2019-124295.CrossRef
9.
16.
Zurück zum Zitat Rousselot P, Loiseau C, Delord M, et al. A report on 114 patients who experienced treatment free remission in a single institution during a 15 years period: long term follow-up, late molecular relapses and second attempts. Blood. 2019;134(Supplement:_1):27. https://doi.org/10.1182/blood-2019-129919.CrossRef Rousselot P, Loiseau C, Delord M, et al. A report on 114 patients who experienced treatment free remission in a single institution during a 15 years period: long term follow-up, late molecular relapses and second attempts. Blood. 2019;134(Supplement:_1):27. https://​doi.​org/​10.​1182/​blood-2019-129919.CrossRef
Metadaten
Titel
Myeloid diseases—Chronic Myeloid Leukemia (CML)—report from ASH 2019 on new developments
verfasst von
Prim. Univ.-Prof. Dr. Andreas L. Petzer
Publikationsdatum
26.05.2020
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2020
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-020-00616-x

Weitere Artikel der Ausgabe 3/2020

memo - Magazine of European Medical Oncology 3/2020 Zur Ausgabe